USE OF VONICOG ALFA: REPORTS OF PREGNANCIES OUTCOME IN TWO PATIENTS WITH TYPE 2 VON WILLEBRAND DISEASES (2VWD)

被引：0
|
作者：
Schell, B. [1 ]
Desprez, D. [2 ]
Sattler, L. [3 ]
de Raucourt, E. [4 ]
Flaujac, C. [1 ]
机构：
[1] Hop Andre Mignot Versailles, Sect Hemostase, Lab Biol Med, Le Chesnay, France
[2] Ctr Ressources & Competences Malad Hemorrag, Le Chesnay, France
[3] Ctr Hosp Reg Univ Strasbourg, Lab Hematol, Strasbourg, France
[4] Hop Andre Mignot Versailles, Ctr Ressources & Competences Malad Hemorrag, Le Chesnay, France
来源：
HAEMOPHILIA | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P215
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [21] Compound heterozygosity for type 2N and type 1 von Willebrand disease (VWD) associated with a homozygous-like type 2N VWD phenotype
    Chan, J
    Mitchell, MJ
    Brown, DA
    Bromidge, ES
    Williams, C
    Smith, MP
    Savidge, GF
    THROMBOSIS AND HAEMOSTASIS, 1999, : 558 - 558
  • [22] Inhibition of Von Willebrand Factor (VWF) by ARC 1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients
    Jilma-Stohlawetz, Petra
    Knoebl, Paul
    Pabinger, Ingrid
    Gilbert, James
    Schaub, Robert G.
    Jilma, Bernd
    BLOOD, 2011, 118 (21) : 1448 - 1448
  • [23] Recessive von Willebrand Disease Type 2 Normandy: Variable Expression of Mild Hemophilia and VWD Type 1
    Michiels, Jan Jacques
    Gadisseur, Alain
    Vangenegten, Inge
    Schroyens, Wilfried
    Berneman, Zwi
    ACTA HAEMATOLOGICA, 2009, 121 (2-3) : 119 - 127
  • [24] Clearance of von willebrand factor (VWF) in type 2 von willebrand disease (VWD): the implications of VWF propeptide (VWFPP) and VWF:Ag levels
    Haberichter, S. L.
    Castaman, G.
    James, P. D.
    Christopherson, P. A.
    Roheghiero, F.
    Lillicrap, D.
    Montgomery, R. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 10 - 10
  • [25] Genetic variations of type 2 and type 3 von Willebrand diseases in Thailand
    Lauhasurayotin, Supanun
    Moonla, Chatphatai
    Ittiwut, Rungnapa
    Ittiwut, Chupong
    Songthawee, Natsaruth
    Komvilaisak, Patcharee
    Natesirinilkul, Rungrote
    Sirachainan, Nongnuch
    Rojnuckarin, Ponlapat
    Sosothikul, Darintr
    Suphapeetiporn, Kanya
    JOURNAL OF CLINICAL PATHOLOGY, 2025, 78 (01) : 57 - 63
  • [26] Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa
    Ryu, Justine H.
    Bauer, Kenneth A.
    Schulman, Sol
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (12) : 3508 - 3510
  • [27] Effectiveness of DDAVP (Minirin Parenteral) in subjects with von Willebrand disease (VWD) type 1 and 2A
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    HAEMOPHILIA, 2010, 16 : 154 - 154
  • [28] Racial disparity in the diagnosis of von willebrand disease (VWD) with particular reference to the diagnosis of type 2M VWD in African Americans
    Branchford, B. R.
    Kautza, B. C.
    Gill, J. C.
    Flood, V. H.
    Friedman, K. D.
    Lee, A.
    Morateck, P.
    Christopherson, P. A.
    Montgomery, R. R.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 630 - 630
  • [29] How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types
    Favaloro, Emmanuel J.
    Mohammed, Soma
    Vong, Ronny
    Oliver, Susan
    Brennan, Yvonne
    Favaloro, James W.
    Curnow, Jennifer
    HAEMOPHILIA, 2021, 27 (01) : 137 - 148
  • [30] Phenotype assignment of Type 2 von Willebrand disease (VWD) variants by a single ELISA-based assay of von Willebrand factor (VWF) functions
    Roberts, J. C.
    Morateck, P. A.
    Christopherson, P. A.
    Yan, K.
    Hoffmann, R. G.
    Gill, J. C.
    Montgomery, R. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 90 - 91
12345